CA-PATIENT-SAFETY-MVMT
The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has selected five individuals for its inaugural Patient Safety Movement Foundation Healthcare Safety Fellowship program. The 12-month, part-time program is focused on providing education and continued development of skills for future healthcare leaders – positioning these stand-out individuals to serve as regional and global leaders in patient safety improvement for years to come.
“We are excited to launch our fellowship program and provide an opportunity to unify and prepare future leaders in patient safety,” said David B. Mayer, MD, CEO of the Patient Safety Movement Foundation. “These individuals have already demonstrated a commitment to improving healthcare, and we look forward to helping them design an individualized education plan that furthers their efforts and collectively helps us in our goal to achieve zero preventable patient deaths by 2030.”
Each of the five fellows will receive guidance from PSMF in designing an actionable plan that is tailored to their background, goals and the specific health needs of their region. In addition, fellows will have opportunities to interact and collaborate with an international network of patient safety and quality mentors, as well as facilitate and lead clinical coaching efforts with hospitals and healthcare organizations across the globe.
This year’s cohort participants include:
-
Luis Ramón Torres Torija Arguelles, MD, MBA
Dr. Luis Torres Torija Arguelles is a physician with a specialty in quality of clinical care from the Tecnológico de Monterrey in Mexico. He currently works as a quality and patient safety coordinator at Hospital Español in Mexico City, Mexico, where he is responsible for the management, design, evaluation, improvement and innovation of clinical care and patient safety processes, incorporating methodologies for continuous improvement and better communication. His efforts to implement all the Patient Safety Movement Foundation’s Actional Patient Safety Solutions have earned his hospital the 5-star Hospital recognition.
-
Carol Gunn, MD
Dr. Carol Gunn attended medical school at UC Davis and completed her internal medicine residency in Portland, Ore., followed by an additional year of training in occupational and environmental medicine at the University of Colorado. In 2007, she opened an independent occupational medicine practice. She thrives on working with individuals and groups advocating for system solutions – whether it be for health, wellness or patient safety.
-
Samar Hassan, PH, MSQ, CPHQ, FISQua
Samar Hassan holds a master’s degree in healthcare quality management and is a registered pharmacist and certified healthcare quality professional with the National Association for Healthcare Quality (NAHQ). In addition, Hassan has worked with the Health Care Accreditation Council (HCAC) in Jordan and the region’s quality improvement and patient safety institution since 2018, where she has been involved in the design, implementation and evaluation of standards for quality and patient safety across health and social care institutions. She has also participated and supported HCAC's advocacy and public awareness programs to synthesize professionals, the public and decision makers on adopting and implementing quality improvement approaches.
-
Elizabeth Namugaya Igaga, MD
Dr. Elizabeth Namugaya Igaga attended Makerere University in Kampala, Uganda, for medical school, as well as her master’s degree in anesthesia and critical care. She is currently doing her clinical practice at the Uganda Heart Institute. Igaga’s interest in patient safety was sparked after multiple firsthand experiences during residency that resulted in near misses or catastrophic outcomes. Since then, she has been passionate about fostering and building a culture of safety in perioperative care in Uganda.
-
Ebikapaye Okoyen, MD, MBBS, MBA, MHPM, FISQua
Dr. Ebikapaye Okoyen works in the Ministry of Health in Yenagoa, Nigeria, as the deputy director and state program manager for Saving One Million Lives Program for Results (SOML PforR) – a World Bank-funded, results-based program financing maternal and child health and nutrition aimed at improving quantity and quality of service. He is a fellow and member of several professional associations including the Nigerian Medical Association, the Society for Quality in Healthcare in Nigeria (SQHN) and is a certified SQHN Health Facility Surveyor with a specialist certificate on the Fundamentals of External Evaluation Surveying from the International Society for Quality in Healthcare (ISQua). He has also published papers in health services research.
To learn more about the Patient Safety Movement Foundation Healthcare Safety Fellowship, visit: https://patient.sm/PR-Fellowship .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals, with more than three million deaths globally, as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero preventable patient harm and death. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005327/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
